

## Medical Coverage Policy | Electromagnetic Navigational Bronchoscopy



**EFFECTIVE DATE:** 01 | 01 | 2020

**POLICY LAST REVIEWED:** 07 | 17 | 2024

### OVERVIEW

Electromagnetic navigation bronchoscopy (ENB) is intended to enhance standard bronchoscopy by providing a 3-dimensional roadmap of the lungs and real-time information about the position of the steerable probe during bronchoscopy. The purpose of ENB is to allow navigation to distal regions of the lungs, so that suspicious lesions can be biopsied and to allow for placement of fiducial markers **placement**.

### MEDICAL CRITERIA

Not applicable

### PRIOR AUTHORIZATION

Not applicable

### POLICY STATEMENT

#### Medicare Advantage Plans and Commercial Products

When flexible bronchoscopy alone, or with endobronchial ultrasound, are considered inadequate to accomplish the diagnostic or interventional objective, electromagnetic navigation bronchoscopy (ENB) may be considered medically necessary to:

- establish a diagnosis of suspicious peripheral pulmonary lesion(s) (CPT code 31627)  
OR
- place fiducial markers within lung tumor(s) prior to treatment (CPT code 31626)

#### Medicare Advantage Plans

Electromagnetic navigation bronchoscopy is not covered for use with flexible bronchoscopy for the diagnosis of mediastinal lymph nodes as well as all other uses not addressed above, as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### Commercial Products

Electromagnetic navigation bronchoscopy is not medically necessary for use with flexible bronchoscopy for the diagnosis of mediastinal lymph nodes as well as all other uses not addressed above, as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for not covered/not medically necessary benefits/coverage.

### BACKGROUND

#### PULMONARY NODULES

Pulmonary nodules are identified on plain chest radiographs, or chest computed tomography scans. Although most nodules are benign, some are cancerous, and early diagnosis of lung cancer is desirable because of the poor prognosis when it is diagnosed later.

Diagnosis

Lung cancer is the leading cause of cancer-related death in the U.S., with an estimated 236,740 new cases and 130,180 deaths due to the disease in 2022. The stage at which lung cancer is diagnosed has the greatest impact on prognosis. Localized disease confined to the primary site has a 60% relative 5-year survival but accounts for only 22% of lung cancer cases at diagnosis. Mortality increases sharply with advancing stage and metastatic lung cancer has a relative 5-year survival of 6%. In addition to tumor stage, other factors such as age, sex, race/ethnicity, and performance status are independent prognostic factors for survival in patients with lung cancer. The average age at diagnosis is about 70 years and most people diagnosed with lung cancer are 65 years of age or older. The lifetime risk of lung cancer is approximately 1 in 15 for men and 1 in 17 for women, with an increased risk in people who smoke. Rates of lung cancer have been dropping among men over the past few decades, but only for about the last decade in women. Black men are about 12% more likely to develop lung cancer compared to White men, although Black men are less likely to develop small cell lung cancer when compared to White men. Among women, the rate of lung cancer is about 16% lower for Black versus White women.

The method used to diagnose lung cancer depends on a number of factors, including lesion size, shape, location, as well as the clinical history and status of the patient. Peripheral lung lesions and solitary pulmonary nodules (most often defined as asymptomatic nodules <6 mm) are more difficult to evaluate than larger, centrally located lesions. There are several options for diagnosing malignant disease, but none of the methods is ideal. Sputum cytology is the least invasive approach. Reported sensitivity rates are relatively low and vary widely across studies; sensitivity is lower for peripheral lesions. Sputum cytology, however, has a high specificity; and a positive test may obviate the need for more invasive testing. Flexible bronchoscopy, a minimally invasive procedure, is an established approach to evaluate pulmonary nodules. The sensitivity of flexible bronchoscopy for diagnosing bronchogenic carcinoma has been estimated at 88% for central lesions and 78% for peripheral lesions. For small peripheral lesions (<1.5 cm in diameter), the sensitivity may be as low as 10%. The diagnostic accuracy of transthoracic needle aspiration for solitary pulmonary nodules tends to be higher than that of bronchoscopy; the sensitivity and specificity are both approximately 94%. A disadvantage of transthoracic needle aspiration is that a pneumothorax develops in 11% to 25% of patients, and 5% to 14% require insertion of a chest tube. Positron emission tomography scans are also highly sensitive for evaluating pulmonary nodules yet may miss lesions less than 1 cm in size. A lung biopsy is the criterion standard for diagnosing pulmonary nodules but is an invasive procedure.

Advances in technology may increase the yield of established diagnostic methods. CT scanning equipment can be used to guide bronchoscopy and bronchoscopic transbronchial needle biopsy but have the disadvantage of exposing the patient and staff to radiation. Endobronchial ultrasound (EBUS) by radial probes, previously used in the perioperative staging of lung cancer, can also be used to locate and guide sampling of peripheral lesions. Endobronchial ultrasound is reported to increase the diagnostic yield of flexible bronchoscopy to at least 82%, regardless of the size and location of the lesion.

#### Marker Placement

Another proposed enhancement to standard bronchoscopy is electromagnetic navigation bronchoscopy. Electromagnetic navigation bronchoscopy is intended to enhance standard bronchoscopy by providing a 3-dimensional roadmap of the lungs and real-time information about the position of the steerable probe during bronchoscopy. The purpose of electromagnetic navigation bronchoscopy is to allow navigation to distal regions of the lungs. Once the navigation catheter is in place, any endoscopic tool can be inserted through the channel in the catheter to the target. This includes insertion of transbronchial forceps to biopsy the lesion. Also, the guide catheter can be used to place fiducial markers. Markers are loaded in the proximal end of the catheter with a guide wire inserted through the catheter.

For individuals who have enlarged mediastinal lymph nodes who receive ENB with flexible bronchoscopy, the evidence includes a RCT and case series. Relevant outcomes are test accuracy and validity, other test performance measures, and treatment-related morbidity. There is less published literature on ENB for diagnosing mediastinal lymph nodes than for diagnosing pulmonary lesions. One RCT identified found higher sampling and diagnostic success with ENB-guided transbronchial needle aspiration than with conventional transbronchial needle aspiration. Endobronchial ultrasound, which has been shown to be

superior to conventional transbronchial needle aspiration, was not used as the comparator. The RCT did not report the diagnostic accuracy of ENB for identifying malignancy, and this was also not reported in uncontrolled studies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## **CODING**

### **Medicare Advantage Plans and Commercial Products**

The following code(s) are considered medically necessary for the conditions listed in the policy statement above:

- 31626** Bronchoscopy, rigid or flexible, including fluoroscopic guidance when performed: with placement of fiducial markers, single or multiple.
- 31627** Bronchoscopy, rigid or flexible, including fluoroscopic guidance when performed; with computer assisted, image-guided navigation (List separately in addition to code for primary procedure)

Note: there is no specific CPT code(s) for electromagnetic navigation bronchoscopy when used for the diagnosis of mediastinal lymph nodes; therefore, providers should report this service with an unlisted procedure code.

## **RELATED POLICIES**

Unlisted Procedures

## **PUBLISHED**

Provider Update, September 2024

Provider Update, September 2023

Provider Update, October 2022

Provider Update, October 2021

Provider Update, May/November 2020

## **REFERENCES**

1. Key Statistics for Lung Cancer. American Cancer Society. <https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html>. Updated February 14, 2022. Accessed April 26, 2022.
2. Surveillance, Epidemiology, and End Results Program (SEER). National Cancer Institute. <https://seer.cancer.gov/statistics-network/> Accessed April 26, 2022.
3. Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*. Sep 2007; 132(3 Suppl): 131S-148S. PMID 17873165
4. Tape TG. Solitary Pulmonary Nodule. In: Black ER, et al, eds. *Diagnostic strategies for common medical problems*, 2nd edition. Philadelphia, PA: American College of Physicians; 1999.
5. Wiener RS, Wiener DC, Gould MK. Risks of Transthoracic Needle Biopsy: How High?. *Clin Pulm Med*. Jan 01 2013; 20(1): 29-35. PMID 23525679
6. Folch EE, Labarca G, Ospina-Delgado D, et al. Sensitivity and Safety of Electromagnetic Navigation Bronchoscopy for Lung Cancer Diagnosis: Systematic Review and Meta-analysis. *Chest*. Oct 2020; 158(4): 1753-1769. PMID 32450240
7. Zhang W, Chen S, Dong X, et al. Meta-analysis of the diagnostic yield and safety of electromagnetic navigation bronchoscopy for lung nodules. *J Thorac Dis*. May 2015; 7(5): 799-809. PMID 26101635
8. Gex G, Pralong JA, Combescure C, et al. Diagnostic yield and safety of electromagnetic navigation bronchoscopy for lung nodules: a systematic review and meta-analysis. *Respiration*. 2014; 87(2): 165-76. PMID 24401166
9. Eberhardt R, Anantham D, Ernst A, et al. Multimodality bronchoscopic diagnosis of peripheral lung lesions: a randomized controlled trial. *Am J Respir Crit Care Med*. Jul 01 2007; 176(1): 36-41. PMID 17379850
10. Khandhar SJ, Bowling MR, Flandes J, et al. Electromagnetic navigation bronchoscopy to access lung lesions in 1,000 subjects: first results of the prospective, multicenter NAVIGATE study. *BMC Pulm Med*. Apr 11 2017; 17(1): 59. PMID 28399830
11. Folch EE, Pritchett MA, Nead MA, et al. Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study. *J Thorac Oncol*. Mar 2019; 14(3): 445-458. PMID 30476574

12. Folch EE, Bowling MR, Pritchett MA, et al. NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the United States. *J Thorac Oncol.* Apr 2022; 17(4): 519-531. PMID 34973418
13. Ost DE, Ernst A, Lei X, et al. Diagnostic Yield and Complications of Bronchoscopy for Peripheral Lung Lesions. Results of the AQuIRE Registry. *Am J Respir Crit Care Med.* Jan 01 2016; 193(1): 68-77. PMID 26367186
14. Chee A, Stather DR, Maceachern P, et al. Diagnostic utility of peripheral endobronchial ultrasound with electromagnetic navigation bronchoscopy in peripheral lung nodules. *Respirology.* Jul 2013; 18(5): 784-9. PMID 23521707
15. Diken OE, Karnak D, Ciledag A, et al. Electromagnetic navigation-guided TBNA vs conventional TBNA in the diagnosis of mediastinal lymphadenopathy. *Clin Respir J.* Apr 2015; 9(2): 214-20. PMID 25849298
16. Wilson DS, Bartlett BJ. Improved diagnostic yield of bronchoscopy in a community practice: combination of electromagnetic navigation system and rapid on-site evaluation. *J Bronchology Interv Pulmonol.* 2007;14(4):227- 232.
17. Kupelian PA, Forbes A, Willoughby TR, et al. Implantation and stability of metallic fiducials within pulmonary lesions. *Int J Radiat Oncol Biol Phys.* Nov 01 2007; 69(3): 777-85. PMID 17606334
18. Anantham D, Feller-Kopman D, Shanmugham LN, et al. Electromagnetic navigation bronchoscopy-guided fiducial placement for robotic stereotactic radiosurgery of lung tumors: a feasibility study. *Chest.* Sep 2007; 132(3): 930-5. PMID 17646225
19. Schroeder C, Hejal R, Linden PA. Coil spring fiducial markers placed safely using navigation bronchoscopy in inoperable patients allows accurate delivery of CyberKnife stereotactic radiosurgery. *J Thorac Cardiovasc Surg.* Nov 2010; 140(5): 1137-42. PMID 20850809
20. Bolton WD, Richey J, Ben-Or S, et al. Electromagnetic Navigational Bronchoscopy: A Safe and Effective Method for Fiducial Marker Placement in Lung Cancer Patients. *Am Surg.* Jul 2015; 81(7): 659-62. PMID 26140883
21. Nabavizadeh N, Zhang J, Elliott DA, et al. Electromagnetic navigational bronchoscopy-guided fiducial markers for lung stereotactic body radiation therapy: analysis of safety, feasibility, and interfraction stability. *J Bronchology Interv Pulmonol.* Apr 2014; 21(2): 123-30. PMID 24739685
22. Minnich DJ, Bryant AS, Wei B, et al. Retention Rate of Electromagnetic Navigation Bronchoscopic Placed Fiducial Markers for Lung Radiosurgery. *Ann Thorac Surg.* Oct 2015; 100(4): 1163-5; discussion 1165-6. PMID 26228602
23. Rong Y, Bazan JG, Sekhon A, et al. Minimal Inter-Fractional Fiducial Migration during Image-Guided Lung Stereotactic Body Radiotherapy Using SuperLock Nitinol Coil Fiducial Markers. *PLoS One.* 2015; 10(7): e0131945. PMID 26158847
24. Bowling MR, Folch EE, Khandhar SJ, et al. Fiducial marker placement with electromagnetic navigation bronchoscopy: a subgroup analysis of the prospective, multicenter NAVIGATE study. *Ther Adv Respir Dis.* Jan-Dec 2019; 13: 1753466619841234. PMID 30958102
25. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. Version 3.2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Accessed April 21, 2022.
26. Detterbeck FC, Mazzone PJ, Naidich DP, et al. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* May 2013; 143(5 Suppl): e78S-e92S. PMID 23649455

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

